E. Goldman

发表

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.

B. Zhu, A. Arfsten, R. Scarborough, 2004, Bioorganic & medicinal chemistry letters.

Guanylpiperidine peptidomimetics: potent and selective bis-cation inhibitors of factor Xa.

R. Nutt, S. Tamura, J. Ho, 2000, Bioorganic & medicinal chemistry letters.

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties.

R. Nutt, S. Tamura, A. Tulinsky, 1996, Journal of medicinal chemistry.

Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors.

C. A. Roberts, K. Masukawa, S. Tamura, 2000, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.

B. Zhu, Liang Bao, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.

J. Woolfrey, B. Zhu, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Lingyan Wang, Gary Park, James Kanter, 2009, Bioorganic & medicinal chemistry letters.

Inhibitory effect of carboxylic acid group on hERG binding.

B. Zhu, Yonghong Song, Priya Eddy, 2006, Bioorganic & medicinal chemistry letters.

Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates

R. Nutt, S. Tamura, M. Lim-Wilby, 1997 .

Rational design, synthesis, and serine protease inhibitory activity of a novel P1-argininal derivative featuring a conformationally constrained P2–P3 bicyclic lactam moiety

S. Tamura, W. Ripka, J. E. Semple, 1997 .

Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.

J. Woolfrey, B. Zhu, G. Park, 2002, Bioorganic & medicinal chemistry letters.

Investigation of the S3 site of thrombin: design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating P1-argininals.

R. Nutt, S. Tamura, J. E. Semple, 1999, Bioorganic & medicinal chemistry letters.

Novel benzo-fused lactam scaffolds as factor Xa inhibitors.

S. Tamura, J. E. Semple, E. Goldman, 1999, Bioorganic & medicinal chemistry letters.

N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.

J. Woolfrey, B. Zhu, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Antimalarial Activities of Novel Synthetic Cysteine Protease Inhibitors

Philip J. Rosenthal, Ajay Singh, Scott J. Kemp, 2003, Antimicrobial Agents and Chemotherapy.

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties.

R. Nutt, S. Tamura, A. Tulinsky, 1996, Journal of medicinal chemistry.